EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial

Yehyun Park iD, Jun Kyu Lee iD, Kwang Hyuck Lee iD, Taejun Kim iD, Sun Hyung Kang iD, Dong-Won Ahn iD, Sung Bum Kim iD, Seong-Jung Kim iD

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70147 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Yehyun Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Benzodiazepines, Endoscopy, Gastrointestinal, Hypnotics and Sedatives, Midazolam. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HANA PHARM, CO., LTD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Remimazolam, a new ultra‐short‐acting benzodiazepine, is a safe and effective option for procedural sedation. Nevertheless, to date, no study has directly compared remimazolam and midazolam in diagnostic upper gastrointestinal endoscopy. This study aimed to evaluate the efficacy and safety of remimazolam compared with those of midazolam in this setting.

Methods

This multicenter, single‐blind, randomized, positive‐control, superiority, investigator‐initiated phase III trial enrolled patients who were scheduled to undergo diagnostic upper gastrointestinal endoscopy at seven academic teaching hospitals from April 2023 to January 2024. Participants were randomly assigned to receive remimazolam or midazolam (1:1 ratio). The primary endpoint was total procedure time, defined as the duration from the first sedative administration to discharge.

Results

Of 133 randomized patients, 132 (remimazolam group, n = 66; midazolam group, n = 66) underwent upper endoscopy with sedation. The total procedure time was significantly shorter in the remimazolam group (30.3 vs. 48.5 min, p < 0.001). Sedation‐related times (i.e., induction, sedation, recovery, and discharge times) were also significantly shorter in the remimazolam group (all p < 0.001). The incidence of adverse events did not significantly differ between the groups; however, the incidence rates of hypotension, bradycardia, and paradoxical reactions were lower in the remimazolam group. When compared to previous sedation experiences, patient satisfaction was higher in the remimazolam group ( p < 0.001).

Conclusions

Compared with midazolam, the use of remimazolam in diagnostic upper gastrointestinal endoscopy allows for faster sedation induction and recovery, more rapid discharge, and higher patient satisfaction compared with previous sedation experiences, while maintaining a safety profile similar to that of midazolam.

Trial registration

ClinicalTrials.gov (NCT05836545)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesEndoscopy, GastrointestinalHypnotics and SedativesMidazolamProcedural SedationAdultAgedFemaleHumansMaleMiddle AgedAnesthesia Recovery PeriodSingle-Blind MethodTime Factors

Stichwörter der Autor:innen

benzodiazepineendoscopymidazolamremimazolamsedation

Substanzen

BenzodiazepinesHypnotics and SedativesMidazolamremimazolam

Autor:innen und Institutionen

  • Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Dongguk University College of Medicine, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
  • Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
  • Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.

ORCID-Profile: Yehyun Park, Jun Kyu Lee, Kwang Hyuck Lee, Taejun Kim, Sun Hyung Kang, Dong-Won Ahn, Sung Bum Kim, Seong-Jung Kim

Förderung

  • HANA PHARM, CO., LTD

Zitieren

APA

Park, Y., Lee, J. K., Lee, K. H., Kim, T., Kang, S. H., Ahn, D. W., Kim, S. B., & Kim, S. J. (2026). Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70147

Vancouver

Park Y, Lee JK, Lee KH, Kim T, Kang SH, Ahn DW, et al. Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70147

BibTeX
@article{Park2026,
  author = {Park, Yehyun and Lee, Jun Kyu and Lee, Kwang Hyuck and Kim, Taejun and Kang, Sun Hyung and Ahn, Dong-Won and Kim, Sung Bum and Kim, Seong-Jung},
  title = {Remimazolam Enables Faster Sedation Induction and Recovery Compared With Midazolam in Diagnostic Upper Gastrointestinal Endoscopy: A Multicenter Randomized Controlled Trial},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70147}
}
Kostenlos starten →